27 articles in Weight Loss, page 1 of 3
Newest first
Phentermine is approved for a few weeks of use. These phentermine alternatives are approved for long-term weight management, ranked on the weight loss in each drug's own label trial, with what each one asks of you in return.
By Arbor Health Team
You've been taking Contrave for months. The cravings quieted down, the scale moved in the right direction, and for the first time in a long time, food stopped running your day.
By Arbor Health Team
The weight-loss industry generates over $70 billion in annual revenue in the United States alone, yet the long-term success rates of most programs remain stubbornly low.
By Arbor Health Team
The scale is the most commonly used tool for tracking weight loss, and for good reason.
By Arbor Health Team
GLP-1 medications like semaglutide and tirzepatide produce remarkable weight-loss results, which are no longer in dispute.
By Arbor Health Team
The price of brand-name GLP-1 medications has been one of the most significant barriers to obesity treatment in the United States.
By Arbor Health Team
More than four in ten American adults live with obesity, and nearly one in ten have severe obesity - numbers that have shown no significant improvement in recent years despite growing awareness of the condition's health consequences.
By Arbor Health Team
Starting Contrave is a meaningful step toward managing your weight, but the medication works best when you support it with the right habits.
By Arbor Health Team
If you're weighing your options for prescription weight loss support, you've likely encountered two names that sit at opposite ends of the obesity pharmacotherapy timeline: orlistat.
By Arbor Health Team
Saxenda and Victoza look nearly identical on the pharmacy shelf: same manufacturer, same injectable pen design, same active ingredient.
By Arbor Health Team
If you've spent any time researching weight-loss medications or type 2 diabetes treatments in the past two years, you've almost certainly encountered two names: liraglutide and semaglutide.
By Arbor Health Team
Polycystic ovary syndrome affects somewhere between 10 and 13 percent of women globally, and up to 70 percent of those cases go undiagnosed.
By Arbor Health Team
